Vitruvian Partners’s RxSight RXST Stock Holding History

Vitruvian Partners’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.72M	Hold	278,865	–	–	1.54%	7
2025 Q4	$2.91M	Buy	278,865 +48,122	+21%	+$483K	2.09%	7
2025 Q3	$2.07M	Hold	230,743	–	–	1.44%	7
2025 Q2	$3M	Hold	230,743	–	–	1.83%	7
2025 Q1	$5.83M	Buy	230,743 +86,443	+60%	+$2.57M	5.56%	5
2024 Q4	$4.96M	Buy	+144,300	New	+$6.51M	4.27%	5

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Vitruvian Partners's RXST Position: Q1 2026 in Review

Vitruvian Partners held its RxSight (RXST) position steady in Q1 2026 at 278,865 shares worth $1.72M. The position accounts for 1.54% of the portfolio, ranked #7.

Vitruvian Partners first reported a position in RXST in Q4 2024 and has held it in 6 quarters since. The position peaked at $5.83M in Q1 2025. 164 funds tracked by Wall St. Rank hold RXST as of Q1 2026.

Vitruvian Partners held 278,865 shares of RxSight worth $1.72M as of Q1 2026.
Vitruvian Partners left its RxSight share count unchanged in Q1 2026.
RxSight made up 1.54% of Vitruvian Partners's portfolio in Q1 2026, its #7 holding.
Vitruvian Partners first reported a position in RxSight in Q4 2024 and has held it in 6 quarters since.
Vitruvian Partners's RxSight position peaked at $5.83M in Q1 2025.
164 funds tracked by Wall St. Rank held RxSight as of Q1 2026.

Based on Vitruvian Partners's 13F filing for Q1 2026, filed 11 May 2026.